MEDFORD, Mass.--(BUSINESS WIRE)--With exciting pre-clinical results showing that its carbohydrate-based vaccine can combat cerebral malaria (CM), which causes inflammation of the brain, Ancora Pharmaceuticals has received another grant from the National Institute of Health (NIH) to research whether its vaccine candidate will also prevent severe malaria anemia (SMA).
